

Financial news for RVNC dated on 2020-06-01: Revance And Mylan To Advance Development Program For Biosimilar To BOTOX; \$30M Milestone Payable To Revance From Mylan

Financial news for RVNC dated on 2020-05-19: Revance Announces Agreement To Acquire HintMD, Will Pay HintMD Shareholders Total Of 8.5M Shares

Financial news for RVNC dated on 2020-05-13: Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C. and Los Angeles County.

Financial news for RVNC dated on 2020-05-07: Revance Therapeutics Q1 EPS \$(1.150) Misses \$(0.900) Estimate

Financial news for RVNC dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetrphase Pharma, Dexcom To Join S&P 500

Financial news for RVNC dated on 2020-05-01: Revance Therapeutics Reports Mylan Biosimilar To BOTOX Program Decision To Extend Beyond Apr. 30, 2020

Financial news for RVNC dated on 2020-04-16: Stifel Maintains Buy on Revance Therapeutics, Lowers Price Target to \$31

Financial news for RVNC dated on 2020-04-01: Mizuho Maintains Buy on Revance Therapeutics, Lowers Price Target to \$35

Financial news for RVNC dated on 2020-03-27: H.C. Wainwright Reiterates Buy on Revance Therapeutics, Lowers Price Target to \$24

Financial news for RVNC dated on 2020-03-23: Goldman Sachs Downgrades Revance Therapeutics to Neutral, Lowers Price Target to \$15

Financial news for RVNC dated on 2020-02-25: Piper Sandler Reiterates Overweight on Revance Therapeutics, Raises Price Target to \$40

Financial news for RVNC dated on 2020-02-25: Needham Maintains Buy on Revance Therapeutics, Raises Price Target to \$36

Financial news for RVNC dated on 2020-02-24: Revance Therapeutics Q4 EPS \$(0.99) Misses \$(0.98) Estimate, Sales \$89K Does Not Comapre To \$2.29M Estimate

Financial news for RVNC dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for RVNC dated on 2020-02-21: Stocks That Hit 52-Week Highs On Friday

Financial news for RVNC dated on 2020-02-21: The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion

Financial news for RVNC dated on 2020-02-20: Stocks That Hit 52-Week Highs On Thursday

Financial news for RVNC dated on 2020-02-18: Piper Sandler Maintains Overweight on Revance Therapeutics, Lowers Price Target to \$37

Financial news for RVNC dated on 2020-02-12: 94 Biggest Movers From Yesterday

Financial news for RVNC dated on 2020-02-11: The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

Financial news for RVNC dated on 2020-02-07: The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns

Financial news for RVNC dated on 2020-02-06: Stocks That Hit 52-Week Highs On Thursday

Financial news for RVNC dated on 2020-02-06: Revance Therapeutics Reports FDA Accepted Biologics License Application For DAXI To Treat Frown Lines

Financial news for RVNC dated on 2020-02-06: The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs

Financial news for RVNC dated on 2020-02-05: Stocks That Hit 52-Week Highs On Wednesday

Financial news for RVNC dated on 2020-02-05: The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data

Financial news for RVNC dated on 2020-02-04: Stocks That Hit 52-Week Highs On Tuesday

Financial news for RVNC dated on 2020-01-23: Mizuho Maintains Buy on Revance Therapeutics, Raises Price Target to \$39

Financial news for RVNC dated on 2020-01-17: The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares

Financial news for RVNC dated on 2020-01-16: Stocks That Hit 52-Week Highs On Thursday

Financial news for RVNC dated on 2020-01-16: The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics

Financial news for RVNC dated on 2020-01-15: The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance

Financial news for RVNC dated on 2020-01-14: The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug

Financial news for RVNC dated on 2020-01-13: 55 Biggest Movers From Friday

Financial news for RVNC dated on 2020-01-10: 40 Stocks Moving In Friday's Mid-Day Session

Financial news for RVNC dated on 2020-01-10: Revance Therapeutics Signs US Distribution Agreement With TEOXANE SA, Making Revance The Exclusive Commercialization Partner Of The Swiss Company's Hyaluronic Acid Technology

Financial news for RVNC dated on 2020-01-09: Revance Therapeutics Offers Corporate, Product Pipeline Update; Shares Anticipated 2020 Milestones

Financial news for RVNC dated on 2019-12-05: Revance Therapeutics Reports Publication Of Pooled Results From Phase 3 Trials For Glabellar Lines In Journal Of American Academy Of Dermatology

Financial news for RVNC dated on 2019-12-05: 72 Biggest Movers From Yesterday

Financial news for RVNC dated on 2019-12-04: Mid-Afternoon Market Update: Dow Rises Over 200 Points; Barnes & Noble Education Shares Slide

Financial news for RVNC dated on 2019-12-04: 38 Stocks Moving In Wednesday's Mid-Day Session

Financial news for RVNC dated on 2019-12-04: Mid-Day Market Update: Crude Oil Up 4%; Revance Therapeutics Shares Plunge

Financial news for RVNC dated on 2019-12-04: Mid-Morning Market Update: Markets Open Higher; G-III Apparel Reports Mixed Q3 Results

Financial news for RVNC dated on 2019-12-04: Revance Therapeutics shares are trading lower after the company priced its 6.5 million share common stock offering at \$17 per share.

Financial news for RVNC dated on 2019-12-04: Revance Therapeutics Prices 6.5M Share Common Stock Offering At \$17/Share

Financial news for RVNC dated on 2019-12-04: 26 Stocks Moving in Wednesday's Pre-Market Session

Financial news for RVNC dated on 2019-12-04: The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug

Financial news for RVNC dated on 2019-12-04: 8 Stocks To Watch For December 4, 2019

Financial news for RVNC dated on 2019-12-03: Revance shares are trading lower after the company announced a proposed public offering of common stock with no disclosed size.

Financial news for RVNC dated on 2019-12-03: Revance Announces Proposed Public Offering Of Common Stock; Size Not Disclosed

Financial news for RVNC dated on 2019-12-03: 75 Biggest Movers From Yesterday

Financial news for RVNC dated on 2019-12-02: 44 Stocks Moving In Monday's Mid-Day Session

Financial news for RVNC dated on 2019-12-02: Benzinga's Top Upgrades, Downgrades For December 2, 2019

Financial news for RVNC dated on 2019-12-02: Goldman Sachs Initiates Coverage On Revance Therapeutics with Buy Rating, Announces \$25 Price Target

Financial news for RVNC dated on 2019-11-25: Revance Therapeutics Highlights Submission Of Biologics License Application To FDA For DAXI To Treat Glabellar Lines

Financial news for RVNC dated on 2019-11-24: The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Arrowhead Earnings And More

Financial news for RVNC dated on 2019-11-04: Revance Therapeutics Q3 EPS \$(0.96) Beats \$(0.98) Estimate, Sales \$46K Miss \$430K Estimate

Financial news for RVNC dated on 2019-11-04: Revance Therapeutics Highlights Publication Of SAKURA 1, 2 Results In Plastic, Reconstructive Surgery: Showed Injection Can Reduce Frown Lines For 24 Weeks Or More

Financial news for RVNC dated on 2019-10-30: Wells Fargo Turns Bullish On Revance Therapeutics After Meeting With Management

Financial news for RVNC dated on 2019-10-30: Wells Fargo Upgrades Revance Therapeutics to Outperform, Raises Price Target to \$20

Financial news for RVNC dated on 2019-10-15: 64 Biggest Movers From Yesterday

Financial news for RVNC dated on 2019-10-14: Revance Announces Mark Foley President and CEO After Dan Browne Resigns

Financial news for RVNC dated on 2019-08-28: The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved

Financial news for RVNC dated on 2019-07-29: 40 Healthcare Stocks Moving In Friday's After-Market Session

Financial news for RVNC dated on 2019-06-11: Barclays Initiates Coverage On Revance Therapeutics with Overweight Rating, Announces \$28 Price Target

Financial news for RVNC dated on 2019-05-09: 28 Stocks Moving In Thursday's Pre-Market Session

Financial news for RVNC dated on 2019-05-09: The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut

Financial news for RVNC dated on 2019-05-08: Revance Therapeutics Q1 EPS \$(0.85) Beats \$(0.87) Estimate, Sales \$278K Miss \$1.14M Estimate

Financial news for RVNC dated on 2019-05-08: The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split

Financial news for RVNC dated on 2019-04-12: The Daily Biotech Pulse: Merck's Keytruda Clinches Another FDA Win, KemPharm Close To NDA Filing For ADHD Drug

Financial news for RVNC dated on 2019-04-11: The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug

Financial news for RVNC dated on 2019-04-10: The Daily Biotech Pulse: Amgen's Bone-Building Osteoporosis Drug Clears FDA Muster, PhaseBio Offering

Financial news for RVNC dated on 2019-04-08: Revance Therapeutics To Present SAKURA 3 Trial Results Presented on Podium at World's Largest Medical Aesthetic Conference

Financial news for RVNC dated on 2019-02-26: Revance Therapeutics Q4 EPS \$(1.12) Misses \$(0.94) Estimate, Sales \$487K Miss \$1.3M Estimate

Financial news for RVNC dated on 2019-02-26: The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote

Financial news for RVNC dated on 2019-02-15: Benzinga's Top Upgrades, Downgrades For February 15, 2019

Financial news for RVNC dated on 2019-02-15: Wells Fargo Initiates Coverage On Revance Therapeutics with Market Perform Rating

Financial news for RVNC dated on 2019-02-14: H.C. Wainwright Initiates Coverage On Revance Therapeutics with Buy Rating, Announces \$25 Price Target

Financial news for RVNC dated on 2019-01-29: Benzinga's Top Upgrades, Downgrades For January 29, 2019

Financial news for RVNC dated on 2019-01-29: Stifel Nicolaus Initiates Coverage On Revance Therapeutics with Buy Rating, Announces \$50 Price Target

Financial news for RVNC dated on 2019-01-28: Revance Therapeutics Shares Indicated Up 1.8% On Light Volume As Hearing Stifel Initiated Coverage With Buy Rating, \$50 Price Target

Financial news for RVNC dated on 2019-01-28: Stocks Which Set New 52-Week Low Mon., Jan. 28, 2019

Financial news for RVNC dated on 2019-01-18: 48 Biggest Movers From Yesterday

Financial news for RVNC dated on 2019-01-17: 34 Stocks Moving In Thursday's Mid-Day Session

Financial news for RVNC dated on 2019-01-17: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for RVNC dated on 2019-01-17: Revance Prices ~5.882M Share Common Stock Offering At \$17/Share

Financial news for RVNC dated on 2019-01-17: 58 Biggest Movers From Yesterday

Financial news for RVNC dated on 2019-01-16: 40 Stocks Moving In Wednesday's Mid-Day Session

Financial news for RVNC dated on 2019-01-16: Revance Therapeutics shares are trading lower after the company announced a \$100 million common stock offering.

Financial news for RVNC dated on 2019-01-16: The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen

Financial news for RVNC dated on 2019-01-16: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for RVNC dated on 2019-01-16: 10 Stocks To Watch For January 16, 2019

Financial news for RVNC dated on 2019-01-15: 8 Stocks Moving In Tuesday's After-Hours Session

Financial news for RVNC dated on 2019-01-15: Revance Therapeutics 8-K Shows Co. Had ~\$194.8M In Cash, Cash Equivalents, Short-Term Investments As Of Jan. 11, 2019

Financial news for RVNC dated on 2019-01-15: Revance Reports \$100M Common Stock Offering

Financial news for RVNC dated on 2018-12-21: The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Financial news for RVNC dated on 2018-12-20: The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum

Financial news for RVNC dated on 2018-12-19: The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

Financial news for RVNC dated on 2018-12-18: The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J \$5B Buyback Plan

Financial news for RVNC dated on 2018-12-06: 50 Biggest Movers From Tuesday

Financial news for RVNC dated on 2018-12-04: Mid-Afternoon Market Update: Dow Drops Over 700 Points; Barnes & Noble Education Shares Plunge

Financial news for RVNC dated on 2018-12-04: 40 Stocks Moving In Tuesday's Mid-Day Session

Financial news for RVNC dated on 2018-12-04: Revance Therapeutics shares are trading up 16.1% after the company announced a license agreement with Fosun Pharma for its RT002 neuromodulator; Revance will receive an upfront payment of \$30 million and tiered royalties on future sales.

Financial news for RVNC dated on 2018-12-04: UPDATE: Revance To Do New Trials For RT002 Related To Forehead Lines, Lateral Canthal Lines (Crow's Feet)

Financial news for RVNC dated on 2018-12-04: UPDATE: Revance Reports RT002 'well-tolerated across over 3,800 treatments in glabellar (frown) lines'

Financial news for RVNC dated on 2018-12-04: UPDATE: Revance Will Receive Upfront Payment Of \$30M, Be Eligible To Receive Added Potential Development, Sales Milestone Payments Of \$230.5M

Financial news for RVNC dated on 2018-12-04: Revance Therapeutics Reports China Market License Deal With Fosun Pharma For RT002; Issues Another Press Release Highlighting RT002 Showed Efficacy, Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program

Financial news for RVNC dated on 2018-12-04: Revance Therapeutics Shares Halted News Pending

Financial news for RVNC dated on 2018-11-28: Stocks Which Set New 52-Week Low Yesterday Tues., Nov. 27, 2018

Financial news for RVNC dated on 2018-11-28: The Daily Biotech Pulse: IntelliPharmaCeutics Generic Antidepressant Gets FDA Nod, GW Pharma Earnings

Financial news for RVNC dated on 2018-11-27: Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 26, 2018

Financial news for RVNC dated on 2018-11-21: The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novellion CEO

Financial news for RVNC dated on 2018-11-19: Stocks Which Set New 52-Week Lows Fri., Nov. 16, 2018

Financial news for RVNC dated on 2018-11-16: Guggenheim Upgrades Revance Therapeutics to Buy, Announces \$41 Price Target

Financial news for RVNC dated on 2018-11-15: Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 14, 2018

Financial news for RVNC dated on 2018-11-15: The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results

Financial news for RVNC dated on 2018-11-05: 74 Biggest Movers From Friday

Financial news for RVNC dated on 2018-11-02: 64 Stocks Moving In Friday's Mid-Day Session

Financial news for RVNC dated on 2018-11-01: Revance Therapeutics Q3 EPS \$(0.91) Beats \$(0.97) Estimate, Sales \$2.362M Beat \$370K Estimate

Financial news for RVNC dated on 2018-11-01: The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

Financial news for RVNC dated on 2018-10-30: Stocks Which Set New 52-Week Low Yesterday, October 29th

Financial news for RVNC dated on 2018-10-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for RVNC dated on 2018-10-25: The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price

Financial news for RVNC dated on 2018-10-11: Revance Therapeutics Appoints Tobin C. Schilke As Chief Financial Officer

Financial news for RVNC dated on 2018-09-18: 50 Biggest Movers From Yesterday

Financial news for RVNC dated on 2018-09-17: JMP: Changing Competitive Landscape Makes Revance Less Appealing

Financial news for RVNC dated on 2018-09-17: 36 Stocks Moving In Monday's Mid-Day Session

Financial news for RVNC dated on 2018-09-17: Stocks Which Set New 52-Week Low Friday, September 14

Financial news for RVNC dated on 2018-09-17: Benzinga's Top Upgrades, Downgrades For September 17, 2018

Financial news for RVNC dated on 2018-09-17: JMP Securities Downgrades Revance Therapeutics to Market Perform

Financial news for RVNC dated on 2018-08-02: Revance Therapeutics Q2 EPS \$(0.94), Inline, Sales \$686K Beat \$510K Estimate

Financial news for RVNC dated on 2018-08-02: The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter

Financial news for RVNC dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for RVNC dated on 2018-06-21: Revance Doses 1st Patient In ASPEN Phase 3 Clinical Program of RT002

Financial news for RVNC dated on 2018-06-05: Jefferies Global Healthcare Begins Today, Presenters Include: Kadmon, Aeri Pharma, Chemed, Orthofix, Revance, Heron Therapeutics, and Dicerna Pharma

Financial news for RVNC dated on 2018-05-30: 42 Biggest Movers From Yesterday

Financial news for RVNC dated on 2018-05-29: Revance Says CFO Lauren Silvernail Resigned As CFO, Says Certain Members Of Co.'s Existing Finance Team Will Assume Duties And Responsibilities Of The Office As They Begin A Search For Its Next CFO

Financial news for RVNC dated on 2018-05-24: Revance Therapeutics Reports Previously-Issued Results Of Phase 2 Study Of RT002 To Treat Moderate-To-Severe Cervical Dystonia Published In 'Movement Disorders Clinical Practice'

Financial news for RVNC dated on 2018-05-22: UBS Global Healthcare Conference 2018 Continues Today, Presenters Include: Civitas Solutions, Revance, Akebia Therapeutics, Bristol-Myers, Senseonics, Lantheus, Acceleron Pharma, and HCA Healthcare

Financial news for RVNC dated on 2018-05-08: Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure

Financial news for RVNC dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for RVNC dated on 2018-04-02: Revance Therapeutics Expands Commercialization Team Ahead of Product Launch of RT002 Injectable

Financial news for RVNC dated on 2018-03-15: Barclays Global Healthcare Conference Concludes Today, Presenters Include: Tenet Healthcare, bluebird bio, and Revance Therapeutics

Financial news for RVNC dated on 2018-03-13: Cantor Fitzgerald Names 8 Upcoming Biotech Catalysts

Financial news for RVNC dated on 2018-03-05: Goldman Sachs Sees 100% Upside In This Biopharma Company

Financial news for RVNC dated on 2018-03-05: Benzinga's Top Upgrades, Downgrades For March 5, 2018

Financial news for RVNC dated on 2018-03-05: Goldman Sachs Initiates Coverage On Revance Therapeutics with Buy Rating, Announces \$60.00 Price Target

Financial news for RVNC dated on 2018-02-21: RBC Capital Global Healthcare Conference Begins Today, Presenters Include: Chemed, Revance, Eagle Pharma, Enanta, Gilead, TransEnterix, Immunogen, and Incyte

Financial news for RVNC dated on 2018-02-15: 13F From Perceptive Advisors Late Wednesday Shows Increased Stake In Abiomed, Neurocrine Biosciences, VBI Vaccines; New Stake In Agile Therapeutics, Amgen, bluebird bio, Arena Pharma, Revance Therapeutics; Exited Stake In Achaogen, OraSure Technologies

Financial news for RVNC dated on 2018-01-29: Barclays Injects Allergan With An Upgrade, Says Valuation Model Has Improved

Financial news for RVNC dated on 2018-01-09: Too Few Visible Catalysts For Revance Push Guggenheim to The Sidelines

Financial news for RVNC dated on 2018-01-09: Benzinga's Top Upgrades, Downgrades For January 9, 2018

Financial news for RVNC dated on 2018-01-09: Guggenheim Downgrades Revance Therapeutics to Neutral

Financial news for RVNC dated on 2018-01-08: Revance Therapeutics Shares Down 5.372%; Earlier Co. Announced Did Not Meet Endpoints In Phase 2a Trial Of RT002

Financial news for RVNC dated on 2018-01-04: Revance Therapeutics Sees FY18 Cash Burn \$117M-\$137M

Financial news for RVNC dated on 2018-01-04: Revance Sees 'Plantar Fasciitis Phase 2a Interim Results by Mid-January'

Financial news for RVNC dated on 2018-01-04: Revance Therapeutics Says 'Expects to Complete RT002 SAKURA Phase 3 Program and Start RT002 Phase 3 Trial for Cervical Dystonia in 2018'

Financial news for RVNC dated on 2017-12-29: 7 Notable Biotechs With Data Expected By Year's End

Financial news for RVNC dated on 2017-12-07: 31 Stocks Moving In Thursday's Mid-Day Session

Financial news for RVNC dated on 2017-12-07: Botox Competition Spurs Argus To Downgrade Allergan

Financial news for RVNC dated on 2017-12-07: Revance Prices 5.33M Share Offering At \$31/Share

Financial news for RVNC dated on 2017-12-06: Guggenheim Initiates Coverage On Revance Therapeutics with Buy Rating, Announces \$42.00 Price Target

Financial news for RVNC dated on 2017-12-06: 36 Biggest Movers From Yesterday

Financial news for RVNC dated on 2017-12-05: Revance Announce \$175M Proposed Stock Offering

Financial news for RVNC dated on 2017-12-05: Mid-Afternoon Market Update: Francesca's Drops On Earnings Miss; Revance Therapeutics Shares Gain

Financial news for RVNC dated on 2017-12-05: 30 Stocks Moving In Tuesday's Mid-Day Session

Financial news for RVNC dated on 2017-12-05: Mid-Day Market Update: Barnes & Noble Education Surges After Q2 Results; Ascena Retail Shares Slide

Financial news for RVNC dated on 2017-12-05: Mid-Morning Market Update: Markets Mostly Higher; Toll Brothers Misses Q4 Views

Financial news for RVNC dated on 2017-12-05: Revance Therapeutics Resumes Trading up ~39% After Meeting Endpoints

Financial news for RVNC dated on 2017-12-05: Revance's RT002 Met Primary and All Secondary Endpoints, Achieves 6-Month Duration in Pivotal SAKURA Phase 3 Trials for Glabellar Lines

Financial news for RVNC dated on 2017-11-29: Revance Plans Phase 3 Program for RT002 Injectable

Financial news for RVNC dated on 2017-11-29: Analyst Says Negative Allergan Headlines Are Priced In, Upgrades Stock

Financial news for RVNC dated on 2017-11-27: Barclays Initiates Coverage On Revance Therapeutics with Overweight Rating, Announces \$31.00 Price Target

Financial news for RVNC dated on 2017-11-20: Revance Therapeutics Reports Orphan Drug Designation For RT002 As Treatment For Cervical Dystonia

Financial news for RVNC dated on 2017-11-17: Benzinga's Top Upgrades, Downgrades For November 17, 2017

Financial news for RVNC dated on 2017-11-17: Mizuho Initiates Coverage On Revance Therapeutics with Buy Rating, Announces \$37.00 Price Target

Financial news for RVNC dated on 2017-11-09: Revance Therapeutics Director Foley Buys 20,000 @ Avg Price: \$26.96 -Form4

Financial news for RVNC dated on 2017-11-02: Revance Sees FY17 Cash Burn \$102M-\$112M

Financial news for RVNC dated on 2017-11-02: Revance Reports Q3 EPS \$(1.01) vs \$(0.93) Est., Sales \$75K vs \$50K Est.

Financial news for RVNC dated on 2017-08-22: Benzinga's Top Upgrades, Downgrades For August 22, 2017

Financial news for RVNC dated on 2017-08-22: JMP Securities Initiates Coverage On Revance Therapeutics with Market Outperform Rating, Announces \$34.00 Price Target

Financial news for RVNC dated on 2017-08-03: Revance Reports Q2 EPS \$(0.90) vs \$(0.94) Est., Sales \$75K

Financial news for RVNC dated on 2017-07-21: 15 Biggest Mid-Day Gainers For Friday

Financial news for RVNC dated on 2017-07-21: Benzinga's Top Upgrades, Downgrades For July 21, 2017

Financial news for RVNC dated on 2017-07-21: Cantor Fitzgerald Initiates Coverage On Revance Therapeutics with Overweight Rating, Announces \$50.00 Price Target

Financial news for RVNC dated on 2017-06-15: Revance Therapeutics Reports Positive BELMONT Phase 2 Trial Results Published in Dermatologic Surgery Journal

Financial news for RVNC dated on 2017-06-05: Revance Reports 'positive' Efficacy Results From RT002 Phase 2 Trial, Showed Clinically Significant Mean Reduction In Primary Endpoint

Financial news for RVNC dated on 2017-05-18: Revance Therapeutics Reports Top-Line 24-Week Duration of Effect Results in All 3 Cohorts in RT002 Injectable Phase 2 Trial

Financial news for RVNC dated on 2017-05-09: Revance Therapeutics Reaffirms FY17 Outlook: Cash Burn \$102M-\$112M, Opex \$108M-\$119M

Financial news for RVNC dated on 2017-05-09: Revance Reports Q1 EPS \$(0.94) vs \$(0.85) Est., Sales \$75K vs \$70k Est.

Financial news for RVNC dated on 2017-05-01: UPDATE: Revance Says is Expanding Phase 2 Program for RT002 to Multi-Center Study with Protocol Updates

Financial news for RVNC dated on 2017-05-01: Revance Therapeutics Reports Update on Phase 2 Program for RT002 Injectable in Mgmt of Plantar Fasciitis

Financial news for RVNC dated on 2017-03-15: Revance Therapeutics Says on March 14, 2017 Co Entered Into Services Agreement With Ajinomoto Althea, Inc; Under Agreement, Althea Has Agreed to Provide Co With Future Source of Commercial Fill/Finish Services for Neuromodulator Products -8-K

Financial news for RVNC dated on 2017-02-27: Revance Reports Q4 EPS \$(0.95) vs. \$(0.84) Est., Sales \$75K vs. \$70k Est.

Financial news for RVNC dated on 2017-01-05: Revance Expects Cash Burn Of \$102-\$112M For FY17

Financial news for RVNC dated on 2016-12-12: Revance Announces Positive 24-Week Duration of Effect in Interim Results from Phase 2 Cervical Dystonia Trial

Financial news for RVNC dated on 2016-12-07: Revance Announces Initiation of Subject Dosing in the SAKURA Phase 3 Clinical Program of RT002 Injectable for the Treatment of Glabellar Lines, Expects Topline Results Q4 2017

Financial news for RVNC dated on 2016-12-07: Revance Announces Initiation of Dosing for SAKURA Phase 3 Trial

Financial news for RVNC dated on 2016-11-29: Benzinga's Top Initiations

Financial news for RVNC dated on 2016-11-29: Aegis Capital Initiates Coverage On Revance Therapeutics at Buy, Announces \$28.00 Target

Financial news for RVNC dated on 2016-11-03: Revance Reports Q3 EPS \$(0.64) vs. Est. \$(0.89), Rev. \$75K vs. Est. \$70K

Financial news for RVNC dated on 2016-11-03: Revance Announces Initiation of Phase 2 Trial of RT002 Injectable to Treat Plantar Fasciitis

Financial news for RVNC dated on 2016-08-04: Revance Reports Q2 EPS \$(0.88) vs. Est \$(0.86)

Financial news for RVNC dated on 2016-07-14: Revance Announces Completion of Pre-Phase 3 Meeting with FDA for RT002 Injectable to Treat Glabellar Lines, Plans To Initiate Phase 3 Program 2H 2016

Financial news for RVNC dated on 2016-06-14: Mid-Afternoon Market Update: Crude Oil Down Over 1%; Motorcar Parts of America Shares Spike Higher

Financial news for RVNC dated on 2016-06-14: 9 Biggest Mid-Day Losers For Tuesday

Financial news for RVNC dated on 2016-06-14: Mid-Day Market Update: Yingli Green Energy Surges Following Q1 Earnings; Infinity Pharmaceuticals Shares Tumble

Financial news for RVNC dated on 2016-06-14: Stocks Hitting 52-Week Lows

Financial news for RVNC dated on 2016-06-14: Mid-Morning Market Update: Markets Mostly Lower; Isle of Capri Casinos Profit Beats Views

Financial news for RVNC dated on 2016-06-14: Brean Downgrades Revance Therapeutics Following RT-001 Fail

Financial news for RVNC dated on 2016-06-14: Benzinga's Top Downgrades

Financial news for RVNC dated on 2016-06-14: 12 Stocks Moving In Tuesday's Pre-Market Session

Financial news for RVNC dated on 2016-06-14: Brean Capital Downgrades Revance Therapeutics to Hold

Financial news for RVNC dated on 2016-06-14: 7 Stocks You Should Be Watching Today

Financial news for RVNC dated on 2016-06-13: 3 Biotechs Posting Big Moves In Monday's After-Hours Session

Financial news for RVNC dated on 2016-06-13: Revance Therapeutics Shares to Resume Trade at 4:30 p.m. EDT

Financial news for RVNC dated on 2016-06-13: Revance Therapeutics Reports Results of RT001 Topical Phase 3 Trial: Did Not Achieve Co-Primary, Other Endpoints

Financial news for RVNC dated on 2016-06-13: Revance Therapeutics Shares Halted News Pending

Financial news for RVNC dated on 2016-05-24: Brean Reiterates Buy Rating On Revance Ahead Of Upcoming Phase 3 Read-Out

Financial news for RVNC dated on 2016-05-09: Revance Therapeutics Reports Q1 EPS \$(0.71) vs \$(0.83) Est., Sales \$75K vs \$70K Est.

Financial news for RVNC dated on 2016-03-23: SunTrust Robinson Humphrey Initiates Coverage on Revance Therapeutics at Buy, Announces \$46.00 PT

Financial news for RVNC dated on 2016-03-16: Brean Capital Initiates Coverage on Revance Therapeutics at Buy, Announces \$48.00 PT

Financial news for RVNC dated on 2016-03-05: Revance Announces Late-Breaking Podium Presentation of Positive 6-Month Duration Results for BELMONT Phase 2 Active Comparator Study of Injectable RT002 at AAD

Financial news for RVNC dated on 2016-03-02: Revance Therapeutics Reports Q4 EPS \$(0.83) Vs Est \$(0.86), Sales \$75.0K Vs Est \$60.0K

Financial news for RVNC dated on 2016-01-07: UPDATE: Revance Therapeutics Expects Dec 31 2015 Cash & Investment Balance To Be Over \$250M

Financial news for RVNC dated on 2016-01-07: Revance Specifies 2016 Clinical Program Milestones, Expects RT001 Topical And RT002 Injectable To Be In Phase 3 Programs In 2016

Financial news for RVNC dated on 2015-12-24: Mid-Morning Market Update: Markets Edge Lower; Cal-Maine Misses Q2 Expectations

Financial news for RVNC dated on 2015-12-24: Watch These Four Stocks On Christmas Eve Morning

Financial news for RVNC dated on 2015-12-23: Revance Therapeutics Reports Phase 2 Results from RT001 Botulinum Toxin Type A Topical Gel for Treatment of Axillary Hyperhidrosis: Both Doses Show Measurable Reduction in Underarm Sweating

Financial news for RVNC dated on 2015-12-14: Revance Names Abhay Joshi, PhD, as COO

Financial news for RVNC dated on 2015-12-07: Revance Therapeutics 13D Filing Shows Holder JP Morgan Chase Holds 10.4% Stake AS Of Nov 30th

Financial news for RVNC dated on 2015-11-23: Benzinga's Top Initiations

Financial news for RVNC dated on 2015-11-23: Guggenheim Securities Initiates Coverage on Revance Therapeutics at Buy, Announces \$55.00 PT

Financial news for RVNC dated on 2015-11-09: Revance Therapeutics Reports Q3 EPS \$(0.81) vs. Est. \$(1.01), Rev. \$75K vs. Est. \$90K

Financial news for RVNC dated on 2015-11-04: Revance Therapeutics Prices 3.25M Share Offering @\$36.00/Share

Financial news for RVNC dated on 2015-11-02: Mid-Day Market Update: Dyax Jumps On Acquisition News; Endurance International Shares Dip

Financial news for RVNC dated on 2015-11-02: Mid-Morning Market Update: Markets Open Higher; Visa To Acquire Visa Europe

Financial news for RVNC dated on 2015-11-02: Morning Market Losers

Financial news for RVNC dated on 2015-11-02: Revance Therapeutics Announces Proposed Public Offering of Common Stock

Financial news for RVNC dated on 2015-11-02: Revance Therapeutics Announces 3.3M Share Secondary Offering

Financial news for RVNC dated on 2015-10-29: Mid-Afternoon Market Update: Rayonier Advanced Materials Gains On Upbeat Results; Rovi Shares Slide

Financial news for RVNC dated on 2015-10-29: Cowen Defends Revance Therapeutics, Advises To Buy On Weakness, Expects RT002 To Yield ~\$1B And Would Buy Shares 'aggressively'

Financial news for RVNC dated on 2015-10-29: Mid-Day Market Update: Build-A-Bear Declines On Weak Results; Lifelock Shares Surge

Financial news for RVNC dated on 2015-10-29: Benzinga's Volume Movers

Financial news for RVNC dated on 2015-10-29: Mid-Morning Market Update: Markets Edge Lower; Mastercard Earnings Beat Estimates

Financial news for RVNC dated on 2015-10-29: Morning Market Gainers

Financial news for RVNC dated on 2015-10-29: Benzinga's Top #PreMarket Gainers

Financial news for RVNC dated on 2015-10-16: Shares That Spiked Before Close

Financial news for RVNC dated on 2015-09-29: Revance Therapeutics Begins Phase 2 Clinical Study of Its Unique Botulinum Toxin Type A for Injection to Treat Cervical Dystonia

Financial news for RVNC dated on 2015-09-28: UPDATE: Revance Therapeutics Says Planning to Issue Interim Results from Phase 3 Trial of Botulinum Toxin During 1H'16

Financial news for RVNC dated on 2015-09-28: Revance Therapeutics Begins Phase 3 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Lateral Canthal Lines

Financial news for RVNC dated on 2015-09-09: Revance Therapeutics Starts Phase 2 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis

Financial news for RVNC dated on 2015-08-06: Revance Therapeutics Reports Q2 Loss \$0.71 Vs Est Loss \$0.84

Financial news for RVNC dated on 2015-07-02: Revance Therapeutics Announces Change in Role of Jacob Waugh, M.D.

Financial news for RVNC dated on 2015-06-05: Jim Cramer Shares His Thoughts On L Brands, Revance Therapeutics And bluebird bio

Financial news for RVNC dated on 2015-06-03: Revance Therapeutics to Initiate Two Key Trials for RT001, Its Topical Botulinum Toxin Type A Investigational Drug Product Candidate

Financial news for RVNC dated on 2015-05-29: Who's The Next Big Pharma Acquisition?

Financial news for RVNC dated on 2015-05-13: Revance Therapeutics Reports Q1 EPS \$(0.65) vs. Est. \$(0.74), Rev. \$75K vs. Est \$130K

Financial news for RVNC dated on 2015-05-04: 8-K from Revance Therapeutics Shows Complaint Filed May 1st Related to City of Warren Police, Fire Systems Retirement Systems, Alleges RT001 Clinical Program Misrepresented

Financial news for RVNC dated on 2015-03-19: Filing from Revance Therapeutics Shows Registration for \$50M Common Stock Offering

Financial news for RVNC dated on 2015-03-04: S-3 from Revance Therapeutics Shows Registration for \$300M Mixed Securities Shelf Offering

Financial news for RVNC dated on 2015-03-02: Revance Therapeutics Reports Q4 EPS \$(0.60), Rev. \$75k

Financial news for RVNC dated on 2015-02-26: Revance Appoints Dr. Philip Vickers to Its BOD

Financial news for RVNC dated on 2015-01-12: Revance Therapeutics Offers Update on Definition of Clinical Program Milestones; Expecting FY14 Adj. Operating Expense in \$42-\$46M Range; Sees FY16 R&D Cost \$52-\$60M, Cash Burn \$74-\$84M

Financial news for RVNC dated on 2015-01-12: Revance Therapeutics Announces FY 2014 and FY 2015 Operating expectations

Financial news for RVNC dated on 2015-01-09: 13G: Franklin Resources Reports 11.6% Stake In Revance Therapeutics

Financial news for RVNC dated on 2015-01-08: Revance Therapeutics Publishes Positive Results From RT002 Phase 1/2 Study

Financial news for RVNC dated on 2015-01-05: Revance Therapeutics Initiates BELMONT Phase 2 Active Comparator Trial of Injectable RT002

Financial news for RVNC dated on 2014-11-13: Morning Market Losers

Financial news for RVNC dated on 2014-10-01: Revance Therapeutics Provides Update On RT001 Clinical Program For The Lead Indication For Crow's Feet Lines

Financial news for RVNC dated on 2014-08-12: Revance Therapeutics Reports Q2 EPS of \$(0.69) vs \$(0.68) Est; Revenue of \$75.0K vs \$100.0K Est

Financial news for RVNC dated on 2014-06-24: UPDATE: Net Proceeds from Revance Offering ~\$131.3M

Financial news for RVNC dated on 2014-06-24: Revance Therapeutics Closes Offering of 4.6M Shares at \$30.50/Share

Financial news for RVNC dated on 2014-06-19: US Stock Futures Flat Ahead Of Jobless Claims

Financial news for RVNC dated on 2014-06-19: Revance Therapeutics Prices 4M Share Offering at \$30,50/Share

Financial news for RVNC dated on 2014-06-18: Amended S-1 from Revance Therapeutics Shows Raised Offering Amount from 3M Previously to 4M Shares

Financial news for RVNC dated on 2014-06-16: Revance Announces 3M Share Offering

Financial news for RVNC dated on 2014-05-13: Revance Therapeutics Reports Q1 EPS of \$(1.93) vs \$(0.87) Est

Financial news for RVNC dated on 2014-04-22: Mid-Afternoon Market Update: Revance Therapeutics Continues to Rally as Markets Hang onto Early Strength

Financial news for RVNC dated on 2014-04-22: Mid-Day Market Update: Allergan Surges On Buyout Offer; Lexmark Shares Slip

Financial news for RVNC dated on 2014-04-22: Mid-Morning Market Update: Markets Gain; McDonald's Posts Lower Profit

Financial news for RVNC dated on 2014-04-22: Morning Market Movers

Financial news for RVNC dated on 2014-04-21: Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Lines

Financial news for RVNC dated on 2014-03-26: Revance Therapeutics Reports Q4 EPS of \$(47.11); Revenue of \$309.0K vs \$100.0K Est

Financial news for RVNC dated on 2014-03-03: Morning Gainers for Mar. 3, 2014: DNDN, PERI, RVNC, ARRY, OMEX, NIHD

Financial news for RVNC dated on 2014-03-03: Cowen & Company Initiates Coverage on Revance Therapeutics at Outperform, Announces \$55.00 PT

Financial news for RVNC dated on 2014-03-03: Piper Jaffray Initiates Coverage on Revance Therapeutics at Overweight, Announces \$44.00 PT

Financial news for RVNC dated on 2014-03-03: BMO Capital Initiates Coverage on Revance Therapeutics at Outperform, Announces \$37.00 PT

Financial news for RVNC dated on 2014-03-03: Benzinga's Top #PreMarket Gainers

Financial news for RVNC dated on 2014-02-06: Shares of Revance Therapeutics Open for Trade at \$21 After Pricing at Just \$16/Share

Financial news for RVNC dated on 2014-02-06: Waiting on Several IPO's This Morning: LADR, EGLT, CMFN, EBIO, RVNC

Financial news for RVNC dated on 2014-01-27: Revance Therapeutics Prices 5M Share IPO at \$14-\$16/ Share